» Articles » PMID: 19235533

Oral Exposure to Inorganic Arsenic: Evaluation of Its Carcinogenic and Non-carcinogenic Effects

Overview
Publisher Informa Healthcare
Specialty Toxicology
Date 2009 Feb 25
PMID 19235533
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Inorganic arsenic, which is extensively metabolised in humans into even more toxic methylated arsenicals, is a potent carcinogen, causing tumours of the skin, lung, urinary bladder, and other organs. It also induces a number of non-cancer effects. Consumption of drinking water highly contaminated by arsenic causes serious health problems in some countries in southeastern Asia, and arsenic poses problems for drinking-water safety world-wide. Existing risk assessments are based on epidemiological studies from regions with high exposure concentrations (in the mg/L range). It is a matter of debate whether these findings are useful at predicting arsenic-induced effects at low concentrations. In recent years numerous epidemiological studies on cancer and non-cancer effects of inorganic arsenic have been published. This work aims at reviewing recent toxicological and epidemiological data on inorganic arsenic with emphasis on effects at low exposure concentrations. Information obtained from epidemiological studies is supplemented with mechanistic data from in vitro and in vivo studies. Various modes of action for arsenic carcinogenicity are discussed. The information gathered was used to evaluate the reliability of existing cancer-risk assessments and to improve current assessments of non-cancer health effects. A tolerable daily dose, based on epidemiological studies on arsenic-induced skin disorders, is presented.

Citing Articles

ARSENIC IN DRINKING WATER AND URINE AND ITS RELATIONSHIP WITH MALIGNANT TUMORS OF URINARY TRACT IN OSIJEK-BARANJA COUNTY, CROATIA.

Vidosavljevic M, Puntaric D, Gvozdic V, Vidosavljevic D, Sijanovic S, Sekerija M Acta Clin Croat. 2024; 62(Suppl2):95-103.

PMID: 38966031 PMC: 11221220. DOI: 10.20471/acc.2023.62.s2.13.


The carcinogenic capacity of arsenic in normal epithelial breast cells and double-positive breast cancer cells.

Zimta A, Cenariu D, Tigu A, Moldovan C, Jurj A, Pop L Med Pharm Rep. 2024; 97(2):184-195.

PMID: 38746032 PMC: 11090272. DOI: 10.15386/mpr-2682.


Update of the risk assessment of inorganic arsenic in food.

Schrenk D, Bignami M, Bodin L, Chipman J, Del Mazo J, Grasl-Kraupp B EFSA J. 2024; 22(1):e8488.

PMID: 38239496 PMC: 10794945. DOI: 10.2903/j.efsa.2024.8488.


Association between urinary arsenic concentration and genetic polymorphisms in Korean adults.

Lee S, Eom S, Lim J, Choi B, Kwon H, Hong Y Toxicol Res. 2024; 40(1):179-188.

PMID: 38223675 PMC: 10786758. DOI: 10.1007/s43188-023-00216-x.


Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma.

Mairinger E, Wessolly M, Buderath P, Borchert S, Henrich L, Mach P Front Oncol. 2023; 13:1252700.

PMID: 38023247 PMC: 10663300. DOI: 10.3389/fonc.2023.1252700.